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Novel mechanisms of gliadin
immunotoxicity?
Eduardo Arranz,1 Jose A Garrote1,2
Coeliac disease (CoD) is a chronic
inﬂammatory intestinal disorder caused
by dietary gluten proteins (prolamines)
from cereals in genetically predisposed
individuals. The disease is manifested by
a lesion which ranges from a complete
transformation of the mucosa with villus
atrophy and crypt cell hyperplasia to the
inﬁltration by lymphocytes of the
epithelium and lamina propria. Gluten is
uniquely resistant to gastrointestinal
digestion, and gluten fragments accumu-
late in the intestine where they trigger
two distinct immune responses, mediated
by the innate and adaptive immunity, and
both contribute to the pathogenesis of
CoD.1 2 Although HLA-DQ2/8 is the
major predisposing factor, other non-HLA
genes, some of them related to the innate
response,3 and/or environmental factors
might contribute to the development of
the disease in a small group of DQ2+
individuals.
Immunostimulatory peptides, as
assessed by using lymphocyte-based
systems, have been identiﬁed in gliadin
and glutenins from wheat gluten, and
homologues from barley and rye. All
peptides which are stimulatory when
tested in vitro are also harmful in vivo.
The best known is the immunogenic
peptide p57-89 (33mer) from a-gliadin,
which is the preferred substrate for tissue
transglutaminase (TGt) and once deami-
nated becomes a potent activator of
gluten-speciﬁc DQ2-restricted CD4+
T cells from patients with CoD, charac-
terised by interferon g (IFNg) production.
Other peptides, like p31-43/49 from
a-gliadin, are toxic in vivo and in vitro,
and have a direct effect on the epithelium,
but do not stimulate gluten-speciﬁc Tcells
from patients with CoD.4 These peptides
induce enterocyte expression of both
interleukin 15 (IL15) and the non-classical
major histocompatibility complex (MHC)
class I chain-related A (MICA) molecules
and HLA-E, as well as IL15 production by
lamina propria mononuclear cells, which
in turn promotes intraepithelial prolifera-
tion and expression of the receptors
NKG2D and CD94, leading to the target
killing of MICA-expressing enterocytes.1 2
The molecular basis of the adaptive
DQ-restricted immune response to gluten
is well understood. Less clear is how
luminal gliadin peptides cross the intes-
tinal epithelium and initiate the speciﬁc
response mediated by lamina propria CD4+
Tcells, and how these gluten-speciﬁc Tcells
control the expansion and activation of
intraepithelial T lymphocytes. Moreover,
little is known about the role of enterocytes
in the uptake and processing of gliadin
peptides, how these peptides activate
innate immunity in the early stages of
intestinal inﬂammation, and why these
effects are only observed in HLA-DQ2+
patients. No speciﬁc receptor has been
described for p31-43, though it has been
reported that this peptide may potentiate
the effect of epidermal growth factor by
interference in the inactivation of its
receptor,5 or that it may induce the early
upregulation of TGt in the epithelium by
a mechanism still unknown.6
The major route of transepithelial
passage of gliadin peptides is by trans-
cytosis, though the underlying mecha-
nisms are not yet clear.2 In active CoD, the
apical-to-basal transport is increased, in an
IFNg-dependent manner, but intra-
epithelial processing is also altered,
allowing intact and/or partially degraded
toxic and immunogenic peptides to enter
the mucosa.7 8 This depends on the
intestinal inﬂammation of untreated CoD,
which may also increase the passive
paracellular diffusion of peptides through
opened epithelial tight junctions via
‘MyD88-dependent’ release of zonulin.9
Other receptor-mediated mechanisms
may contribute to the translocation of
intact gliadin peptides to the lamina
propria, by using a protected pathway
driven by gluten-speciﬁc secretory IgA via
transferrin receptor CD71,10 or involving
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myeloid dendritic cells expressing both
HLA-DQ and surface TGt.11
In this issue of Gut, the papers by
Luciani et al12 (see page 311) and by
Zimmer et al13 (see page 300) focus
on some of the unsolved questions of
CoD pathogenesis. By using epithelial
cell lines and human duodenal biopsies,
the authors analysed the epithelial
uptake and processing of gliadin peptides
via intracellular compartments, which
result in the activation of new signalling
pathways of mucosal inﬂammation,12 and
different routes of antigen presentation.13
These papers describe two different path-
ways of endocytosis and delivery of gliadin
peptides to paranuclear vesicles which
may be relevant in the initial steps of the
development of the disease, though the
mechanisms responsible for the segrega-
tion and/or accumulation of these peptides
remain obscure. Rather than a primary
epithelial defect in patients with CoD, this
is probably due to the intrinsic properties
of p31-43/49, because other peptides are
removed from the vesicular system.
In the study by Luciani et al,12 all
peptides can reach the late endosomes and
lysosomes, but p31-43 (unlike other
peptides) is retained in the latter where it
generates a pro-oxidative environment
which induces TGt activation and degra-
dation of peroxisome proliferator-activated
receptor (PPAR) g, a modulator of intes-
tinal inﬂammation. This mechanism
might explain why patients with CoD
relapse after gluten reintroduction, even
when signs of inﬂammation are absent.
The early effects of gliadin might be rela-
tively common,14 but signalling pathways
may undergo downregulatory control in
non-CoD individuals. However, in HLA-
DQ2+ patients, the innate related signal
may be ampliﬁed by other factors: expres-
sion of cytokine-related genes,3 TGt acti-
vation and PPARg degradation,12 or high
IL15Ra expression,15 leading to the trig-
gering of an adaptive immune response
mediated by gluten-reactive CD4 Tcells.
Zimmer et al13 conﬁrmed that both
toxic and immunogenic peptides are
internalised by the enterocytes, but they
follow different endocytotic pathways, as
shown by p31-49 which bypasses HLA-
DR+ late endosomes and escapes antigen
presentation at the basolateral membrane,
though we do not know the fate of these
peptides: are they translocated by
a protected pathway, or degraded in
endosomes? The authors hypothesised
that HLA-DR+ enterocytes generate
a tolerogenic effect in contrast to the
immunostimulatory effect mediated by
HLA-DQ+ lamina propria dendritic cells.
Still, these mechanisms have to be
validated in vivo, and further studies
should evaluate the uptake and processing
of both toxic and immunogenic gliadin
peptides by normal and inﬂamed mucosa
(or in the early and late stages of the
disease). Moreover, its speciﬁcity to the
CoD intestine has to be conﬁrmed, and it
would be interesting to know how early
inﬂammation is controlled by non-CoD
individuals: is this related to HLA/non-
HLA genes, or to other local or environ-
mental factors? These results open the
way for alternative therapies based on the
use of antioxidants, TGt inhibitors (and
PPARg modulators), or the re-induction of
tolerance.
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